Nanoparticles for hepatitis B treatment, preparation method of nanoparticles and therapeutic vaccine

A nanoparticle and hepatitis B technology, applied in the field of therapeutic vaccines, can solve the problems of ineffective activation of cellular immunity, failure to achieve ideal therapeutic effect, large nanoparticle size, etc., to achieve breaking immune tolerance, round shape, particle size The effect of uniform diameter

Pending Publication Date: 2020-10-02
SUN YAT SEN UNIV
View PDF11 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] The hepatitis B therapeutic vaccines currently under study mainly include hepatitis B surface antigen (HBsAg) vaccine, hepatitis B surface antigen-hepatitis B surface antibody complex vaccine, hepatitis B surface antigen-hepatitis B core antigen vaccine, hepatitis B surface antigen epitope vaccine and hepatitis B DNA vaccine, etc. , the vaccines in these studies all use traditional adjuvants such as aluminum adjuvants and saponins, which can activate a certain amount of humoral immunity, but cannot effectively activate cellular immunity
However, cellular immunity plays a v

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Nanoparticles for hepatitis B treatment, preparation method of nanoparticles and therapeutic vaccine
  • Nanoparticles for hepatitis B treatment, preparation method of nanoparticles and therapeutic vaccine
  • Nanoparticles for hepatitis B treatment, preparation method of nanoparticles and therapeutic vaccine

Examples

Experimental program
Comparison scheme
Effect test

Example Embodiment

[0060] Example 1 Preparation method of nanoparticles

[0061] 1. Method

[0062] 1. Solution preparation

[0063] (1) Disperse chitosan in sterilized distilled water, add 1% acetic acid with a volume fraction under magnetic stirring, stir overnight, and filter with filter paper to obtain a chitosan solution with a concentration of 0.45 mg / mL .

[0064] (2) Disperse heparin in sterilized distilled water, stir under magnetic stirring for 5 minutes, and filter with a 0.22 μm filter to obtain a heparin solution with a concentration of 0.3 mg / mL.

[0065] (3) The HBsAg antigen was dissolved in distilled water and filtered with a 0.22 μm filter membrane to obtain an HBsAg antigen solution with a concentration of 10 μg / mL.

[0066] (4) Dissolve HBcAg in distilled water and filter with a 0.22μm filter membrane to obtain an HBcAg solution with a concentration of 10μg / mL.

[0067] (5) Dissolve CpG in distilled water, stir for 5 min under magnetic stirring, and filter with a 0.22 μm filter to obtai...

Example Embodiment

[0092] Example 2 Preparation method of nanoparticles

[0093] 1. Method

[0094] 1. Solution preparation

[0095] (1) Disperse chitosan in sterilized distilled water, add 1% acetic acid with a volume fraction under magnetic stirring, stir overnight, and filter with filter paper to obtain a chitosan solution with a concentration of 0.45 mg / mL .

[0096] (2) Disperse heparin in sterilized distilled water, stir for 5 min under magnetic stirring, and filter with a 0.22 μm filter membrane to obtain a heparin solution with a concentration of 0.3 mg / mL.

[0097] (3) The HBsAg antigen was dissolved in distilled water and filtered with a 0.22 μm filter membrane to obtain an HBsAg antigen solution with a concentration of 10 μg / mL.

[0098] (4) Dissolve HBcAg in distilled water and filter with a 0.22μm filter membrane to obtain an HBcAg solution with a concentration of 10μg / mL.

[0099] (5) Dissolve CpG in distilled water, stir for 5 min under magnetic stirring, and filter with a 0.22 μm filter to ...

Example Embodiment

[0118] Example 3 Preparation method of nanoparticles

[0119] 1. Method

[0120] 1. Solution preparation

[0121] (1) Disperse chitosan in sterilized distilled water, add 1% acetic acid with a volume fraction under magnetic stirring, stir overnight, and filter with filter paper to obtain a chitosan solution with a concentration of 0.45 mg / mL .

[0122] (2) Disperse heparin in sterilized distilled water, stir for 5 min under magnetic stirring, and filter with a 0.22 μm filter membrane to obtain a heparin solution with a concentration of 0.3 mg / mL.

[0123] (3) The HBsAg antigen was dissolved in distilled water and filtered with a 0.22 μm filter membrane to obtain an HBsAg antigen solution with a concentration of 10 μg / mL.

[0124] (4) Dissolve HBcAg in distilled water and filter with a 0.22μm filter membrane to obtain an HBcAg solution with a concentration of 10μg / mL.

[0125] (5) Dissolve CpG in distilled water, stir for 5 min under magnetic stirring, and filter with a 0.22 μm filter to ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Particle sizeaaaaaaaaaa
Particle sizeaaaaaaaaaa
Particle sizeaaaaaaaaaa
Login to view more

Abstract

The invention discloses nanoparticles for hepatitis B treatment, a preparation method of the nanoparticles and a therapeutic vaccine. The nanoparticles comprise HBsAg or HBcAg protein, an immunologicadjuvant CpG, a cationic polymer and an anionic polymer. The invention provides the nanoparticles simultaneously wrapping the HBsAg and the immunologic adjuvant and the nanoparticles simultaneously wrapping the HBcAg and the immunologic adjuvant; the nanoparticles are regular in shape, round in appearance, smooth in surface, good in dispersity, uniform in particle size, high in encapsulation efficiency and free of obvious adhesion, damage, collapse and other phenomena; the immunologic adjuvant CpG is adopted; the nanoparticles are small in particle size and have higher immunocompetence; and the two types of nanoparticles are mixed for use to break immune tolerance, activate immune response, effectively remove HBV and cure chronic hepatitis B.

Description

technical field [0001] The present invention relates to the technical field of therapeutic vaccines, and more specifically, relates to a nanoparticle for treating hepatitis B, a preparation method thereof and a therapeutic vaccine. Background technique [0002] Hepatitis B virus (HBV) infection is the most common chronic viral infection in the world. About 2 billion people in the world are infected with HBV, and 350 million of them become chronic hepatitis B carriers. In the process of chronic hepatitis B infection, low-level inflammation of the liver will be caused, accompanied by transient high-level inflammation and activation of liver fibrosis, which will lead to liver fibrosis and cirrhosis, and eventually lead to compensatory liver disease and occurrence of hepatocellular carcinoma. Chronic hepatitis B infection is endemic in many parts of the world, particularly in the Western Pacific and Africa. As early as in the Global Burden of Disease Study in 2010, HBV infecti...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/51A61K47/36A61K47/34A61K39/29A61K39/39A61P1/16A61P31/20
CPCA61K9/5161A61K9/5146A61K39/12A61K39/39A61P1/16A61P31/20A61K2039/55561C12N2730/10134
Inventor 刘利新乔冬冬陈永明
Owner SUN YAT SEN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap